title: Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
abstract: OBJECTIVE
  To validate the Memorial Sloan-Kettering Cancer Center (MSKCC) and Heng models with metastatic renal cell carcinoma treated with sunitinib, and to investigate prognostic factors in these patients.
  
  
  METHODS
  This study included 106 patients with metastatic renal cell carcinoma who were treated with sunitinib from April 2007 to July 2012 including 35 patients who received systemic treatment before sunitinib and 71 that were naive to systemic treatment. Patients were evaluated using the MSKCC and Heng models, and the significance of several prognostic factors were evaluated.
  
  
  RESULTS
  The application of the MSKCC and Heng risk criteria resulted in stratification into 3 groups (favorable, intermediate, and poor risk) with distinctly different overall survival (OS) curves (P < 0.001 and P < 0.001, respectively), for the pretreated patients (P < 0.001 and P < 0.001, respectively). The Heng model had slightly better discriminatory ability (χ (2) = 30.82, Harrell's C = 0.6895) than the MSKCC model (χ (2) = 25.13, Harrell's C = 0.6532). Multivariate analysis revealed that the absence of nephrectomy and no hypertension at baseline, along with elevated C-reactive protein levels, were independent risk factors for poorer OS.
  
  
  CONCLUSIONS
  The MSKCC and Heng model were both valid models for predicting OS. The no nephrectomy, no hypertension at baseline, and high C-reactive protein levels were independently associated with poorer OS.
authors.affiliation: Department of Urology, Wonkwang University College of Medicine, Iksan, Republic of Korea.
authors.forename: Whi-An
authors.initials: WA
authors.lastname: Kwon
authors.forename: In-Chang
authors.initials: IC
authors.lastname: Cho
authors.forename: Ami
authors.initials: A
authors.lastname: Yu
authors.forename: Byung-Ho
authors.initials: BH
authors.lastname: Nam
authors.forename: Jae Young
authors.initials: JY
authors.lastname: Joung
authors.forename: Ho Kyung
authors.initials: HK
authors.lastname: Seo
authors.forename: Kang Hyun
authors.initials: KH
authors.lastname: Lee
authors.forename: Jinsoo
authors.initials: J
authors.lastname: Chung
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D049451:Nomograms; D011379:Prognosis; D011758:Pyrroles / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D000077210:Sunitinib; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib